ReviewDrugs2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening.Molecules (Basel, Switzerland) · 2026Article
- Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?International journal of molecular sciences · 2022Review
- Article
- Article
- CD38-Directed Therapies for Management of Multiple Myeloma.ImmunoTargets and therapy · 2021Review
- Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak.Oncotarget · 2020Article
- Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy.Cancer management and research · 2020Review
- Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.Haematologica · 2018Article
- Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.Leukemia · 2018Article
- Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Haematologica · 2017Article
- New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Biologics : targets & therapy · 2017Review
- Role of daratumumab in transfusion medicine: a must know entity.Revista brasileira de hematologia e hemoterapiaArticle
- Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.Asia-Pacific journal of oncology nursingArticle
- Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Journal of the advanced practitioner in oncologyReview
- Role of dithiothreitol in the resolution of pretransfusion immunohematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.Asian journal of transfusion scienceArticle
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 15 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number of mAbs directed at myeloma cell surface molecules are in development. Daratumumab is a CD38 mAb that has demonstrated substantial activity and good tolerability in four phase I, phase I/II and phase II studies as monotherapy, as well as in combination with current standard treatments in MM. The positive results obtained in the relapsed/refractory setting in patients with advanced-stage disease and in a small number of patients with newly diagnosed disease provide the rationale for the investigation of the agent in a number of ongoing phase III trials. mAbs are generally better tolerated than conventional chemotherapy; however, their use requires other special considerations. Such factors include those common to all mAbs, namely infusion-related reactions, but also factors that are observed with mAbs used in myeloma, such as interference with response assessment, or factors that are related to CD38 mAbs such as daratumumab, for instance blood typing interference. Our review provides an overview of the results from the daratumumab clinical trials conducted to date, as well as practical management considerations for the use of daratumumab based on our experience with the agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.